Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 21, Issue 4, Pages 1629-1632Publisher
ELSEVIER SCIENCE INC
DOI: 10.1111/ajt.16349
Keywords
clinical research; practice; immunosuppressant; immunosuppression; immune modulation; liver allograft function; dysfunction; liver transplantation; hepatology; organ transplantation in general; T cell biology
Categories
Funding
- ProjektDEAL
Ask authors/readers for more resources
Currently, there is limited understanding of the duration and effectiveness of immunity following SARS-CoV-2 infection, as well as potential adverse late effects. This uncertainty raises questions about the safety of offering liver transplantation to patients who have recovered from COVID-19. In this case report, successful liver transplantation was performed shortly after recovery, but partial seroreversion and prolonged shedding of viral RNA were observed.
To date, little is known about the duration and effectiveness of immunity as well as possible adverse late effects after an infection with SARS-CoV-2. Thus it is unclear, when and if liver transplantation can be safely offered to patients who suffered from COVID-19. Here, we report on a successful liver transplantation shortly after convalescence from COVID-19 with subsequent partial seroreversion as well as recurrence and prolonged shedding of viral RNA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available